{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The incidence of overall CAT (inclusive of both symptomatic and asymptomatic events) will be assessed and reported with 95% confidence interval.","groups":[{"description":"Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.\n\nXisomab 3G3: Given IV or via catheter","id":"OG000","title":"Supportive Care (Xisomab 3G3)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eight of nine participants underwent screening ultrasound for catheter thrombosis. One patient had their catheter removed prior to screening ultrasound.","reportingStatus":"POSTED","timeFrame":"Up to end of treatment visit (day 18)","title":"Incidence of Catheter-associated Thrombosis (CAT)","type":"PRIMARY","unitOfMeasure":"Participants"}